The Global Medtech Industry: Rewiring Medtech in a Post-Pandemic World
The medtech industry is undergoing rapid change to address evolving global market dynamics. This has been further accelerated by the pandemic. This white paper from IQVIA – an associate member of AdvaMed® – discusses how global markets and specific therapeutic areas are poised for growth over the next decade. Read this white paper to help inform business strategy.
Related Reading
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 9/12
September 12, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 9/5
September 5, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 8/22
August 22, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 8/15
August 19, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Scott Whitaker Op-Ed: Medtech is vital to a healthier America
August 12, 2025
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 7/25
July 25, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 25, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 7/18
July 18, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 18, 2025.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed® Advancements: Q2 2025 Report
July 17, 2025
Discover our Q2 report highlighting key industry wins, tariff updates, and strategic progress driving medtech innovation and advocacy forward.